Drug
Secukinumab
Secukinumab: highest development phase Post-Market, developed by Novartis. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Secukinumab 300 mg NCT02690701 | Post-Market | Chronic Plaque Psoriasis |
| COSENTYX | Approved | |
| Secukinumab NCT06751238 | Phase 1 | Juvenile Psoriatic Arthritis |
Latest
No recent events.
Follow Secukinumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.